KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 95 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q2 2022. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,296,857 | +21.5% | 650,366 | -1.5% | 0.72% | +36.2% |
| Q2 2023 | $9,294,546 | +31.7% | 660,124 | +0.7% | 0.53% | +31.4% |
| Q1 2023 | $7,054,859 | -32.4% | 655,656 | -6.0% | 0.40% | -33.1% |
| Q4 2022 | $10,443,487 | +8.5% | 697,162 | -7.0% | 0.60% | +7.3% |
| Q3 2022 | $9,629,000 | +22.0% | 749,933 | -7.9% | 0.56% | +46.1% |
| Q2 2022 | $7,894,000 | -2.2% | 814,673 | +0.3% | 0.38% | +18.6% |
| Q1 2022 | $8,071,000 | -3.8% | 811,922 | +13.9% | 0.32% | +8.1% |
| Q4 2021 | $8,390,000 | -0.1% | 712,807 | -3.3% | 0.30% | -3.9% |
| Q3 2021 | $8,399,000 | -17.9% | 737,374 | +0.4% | 0.31% | -14.8% |
| Q2 2021 | $10,230,000 | -17.1% | 734,366 | +10.2% | 0.36% | -9.5% |
| Q1 2021 | $12,334,000 | +16.4% | 666,353 | +11.1% | 0.40% | +7.8% |
| Q4 2020 | $10,593,000 | – | 599,517 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 2,374,392 | $36,376,000 | 4.43% |
| Opaleye Management Inc. | 338,000 | $8,778,000 | 1.72% |
| Lion Point Capital, LP | 495,748 | $7,594,000 | 1.67% |
| Fairmount Funds Management LLC | 212,746 | $3,259,000 | 1.38% |
| Vivo Capital, LLC | 1,151,622 | $17,643,000 | 1.02% |
| Spearhead Capital Advisors, LLC | 270,117 | $4,138,000 | 0.79% |
| Integral Health Asset Management, LLC | 120,000 | $1,838,000 | 0.56% |
| Endurant Capital Management LP | 117,480 | $1,800,000 | 0.53% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,990 | $3,983,000 | 0.39% |
| Ikarian Capital, LLC | 342,998 | $5,254,000 | 0.38% |